HSBC Holdings
RNAC icon

HSBC Holdings’s Cartesian Therapeutics RNAC Stock Holding History

HSBC Holdings’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,000
Closed -$834K – 2715
2023
Q1 		$834K Buy
+20,000
New +$940K ﹤0.01% 1850
2021
Q2 		– Sell
-415
Closed -$56K – 3059
2021
Q1 		$56K Buy
+415
New +$51.5K ﹤0.01% 2662

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's RNAC Position: Q2 2023 in Review

HSBC Holdings sold out of Cartesian Therapeutics (RNAC) in Q2 2023, closing a stake of 20,000 shares — an estimated $834K sold.

HSBC Holdings first reported a position in RNAC in Q1 2021 and held it in 2 quarters. The position peaked at $834K in Q1 2023. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2023.

  • HSBC Holdings reported no remaining Cartesian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • HSBC Holdings sold 20,000 Cartesian Therapeutics shares in Q2 2023, an estimated $834K.
  • HSBC Holdings first reported a position in Cartesian Therapeutics in Q1 2021 and held it in 2 quarters.
  • HSBC Holdings's Cartesian Therapeutics position peaked at $834K in Q1 2023.
  • 92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2023.

Based on HSBC Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.